. 2021 Apr 27;268(12):4655–4666. doi: 10.1007/s00415-021-10568-9

Table 1.

Sociodemographic and clinical baseline characteristics of the PD-MCI subgroups that are included in the 6 respective 12 months follow-up analyses

	6 months follow-up			12 months follow-up
	Cognitive training (n = 28)	Physical training (n = 26)	p	Cognitive training (n = 25)	Physical training (n = 24)	p
Age (years)	67.18 ± 7.01	67.50 ± 8.71	0.881^a	67.04 ± 6.63	67.08 ± 8.85	0.985^a
Sex
Male (%)	21 (75%)	15 (57.7%)	0.250^c	19 (76%)	14 (58.3%)	0.232^c
Female (%)	7 (25%)	11 (42.3%)	0.250^c	6 (24%)	10 (41.7%)	0.232^c
Years of education	13.43 ± 3.84	13.96 ± 3.33	0.868^b	13.20 ± 3.74	13.92 ± 3.20	0.769^b
Age of PD symptom onset (years)	58.11 ± 8.61	59.35 ± 9.04	0.613^a	57.92 ± 7.60	59.25 ± 9.36	0.591^a
Age at PD diagnosis (years)	59.29 ± 8.87	59.96 ± 9.11	0.784^a	59.12 ± 8.07	59.88 ± 9.15	0.764^a
PD duration (months)	93.07 ± 66.32	89.54 ± 44.88	0.917^b	93.52 ± 68.0	85.67 ± 44.53	0.772^b
Hoehn and Yahr stage
1 (%)	2 (7.1)	6 (23.1)	0.113^d	2 (8.0)	5 (20.8)	0.273^d
2 (%)	16 (57.1)	17 (65.4)		15 (60.0)	16 (66.7)
3 (%)	9 (32.1)	3 (11.5)		7 (28.0)	3 (12.5)
4 (%)	1 (3.6)	0		1 (4.0)	0
5 (%)	0	0		0	0
UPDRS-III	25.43 ± 13.26	25.08 ± 12.80	0.931^b	25.04 ± 12.34	26.21 ± 12.68	0.681^b
LEDD	890.80 ± 519.80	739.58 ± 411.85	0.411^b	935.22 ± 530.77	739.92 ± 425.73	0.250^b
ApoE4 carriers	5 (17.9%)	3 (11.5%)	0.711^d	4 (16%)	3 (12.5%)	1.000^d
BDI-II	8.43 ± 5.65	7.28 ± 4.11	0.616^b	8.28 ± 5.76	7.57 ± 4.17	0.868^b
MoCA	25.0 ± 2.22	24.23 ± 3.15	0.340^b	25.08 ± 2.08	24.13 ± 3.26	0.266^b

Results are given in mean ± standard deviation

BDI Beck Depression Inventory, LEDD Levodopa equivalent daily dose, MoCA Montreal Cognitive Assessment, PD Parkinson’s Disease, UPDRS Unified Parkinson’s Disease Rating Scale

^at test

^bMann–Whitney U test

^cχ² test

^dFisher’s exact test